eQ Plc Investor news28 July 2025, at 3:15 p.m. eQ Plc will publish its January-June 2025 half year financial report on Tuesday 5 August 2025 at around 8:00 a.m. eQ will present the result to press, investors and analysts in a press conference to be held on 5 August 2025 at 11:30 a.m. The press conference will held at eQ's head office in Helsinki, address Aleksanterinkatu 19, 5th floor, 00100 Helsinki and it is also possible to participate via webcast. The webcast participation requires a registration. The ...

Nasdaq-listed Brera’s Purchase of SS Juve Stabia and City’s Ownership of Palermo FC Brings the Two Groups Together to Compete in a Top-Five Soccer Market; Manchester City FC is another key holding of CFG, majority-owned by Abu Dhabi United Group Palermo FC President Dario Mirri (left) and Brera Executive Chairman Dan McClory (right) at the recent Serie B Owners’ Meetings in Rome on July 23, 2025 Palermo FC President Dario Mirri (left) and Brera Executive Chairman Dan McClory (right) at the recent Serie B ...

The Company will Develop a New Product to Enable Advanced Tactical Video and Edge Computing Capabilities Rehovot, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in video and artificial intelligence (“AI”) - based edge computing technology, today announced that it has received a $144,000 order. The order, placed by a customer in the defense industry, is for the design and development of an advanced tactical video and AI-based p ...

Miami, FL, July 28, 2025 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a leading digital energy and infrastructure company, today announced the closing on July 25, 2025 of its upsized offering of 0.00% convertible senior notes due 2032 (the “notes”). The aggregate principal amount of the notes sold in the offering was $950 million. MARA also granted the initial purchasers an option to purchase up to an additional $200 million aggregate principal amount of the notes within ...

Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration. Troculeucel was shown to internalize and digest amyloid and α-synuclein proteins in vitro and to improve CSF levels of amyloid, α-synuclein, and p-tau in Phase 1 patients in a largely dose-dependent manner. Troculeucel identifies and eliminates auto-activated T cells without disrupting resting T cells in vitr ...

Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that its Board of Directors approved a 15% stock dividend, 0.15 shares of common stock per share of common stock and per each common stock equivalent with dividend rights. This stock grant reflects IMUNO ...

Rehovot, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (Nasdaq: STKH), a global leader in 3D-printing technology for structured alt-protein production, announced today that it has received a positive Written Opinion from the International Searching Authority (ISA) regarding its international patent application PCT/US 24/34252. The application covers the printing system of the company’s HD144 printer for plant-based fish, which is based on its proprietary DLS® (Drop Location in Space) dro ...

PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Reviews in Urology of results from a Phase 3b study evaluating the feasibility of administering ZUSDURI™ (mitomycin) for intravesical solution (formerly known as UGN-102) in the home setting. The study, titled "Home Instillation of UGN-102 for Primary Chemoablation of ...

Vertex's 2025 Mid-Year Report reveals more than 400 implemented changes to U.S. sales tax rates and rules nationwide, highlighting growing compliance complexity for businessesKING OF PRUSSIA, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today released its 2025 Mid-Year U.S. Rates and Rules Report. The findings indicate that 408 sales tax rate changes and new rates were issued through June 30, 2025 – a 24% i ...

ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world’s first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat comp ...